Company news

Recently, CYTOWIZ successfully completed a round of A+ financing of tens of millions of RMB, led by Silicon Harbor Capital and followed by Zhangke Woerun and Jinchang Qiya. This round of financing is another successful financing for CYTOWIZ after last year's Series A. The funds raised will be mainly used for the system certification of the fully automated Liquid-based Thin Layer Preparation (LTP) staining and sealing machine and the artificial intelligence cervical cancer screening system, the promotion of commercialization of the products, the expansion of production lines, and the research and development of new products in the field of cellular analysis related areas, which will once again inject the strength for the rapid development of CYTOWIZ.

CYTOWIZ officially started the project in 2019, focusing on the cervical cancer cytology screening system solution, providing a complete intelligent solution for cell analysis, with products ranging from sample collection and preservation, to automated pre-processing preparation and staining and sealing all-in-one machine, high-definition microscopy scanning system and AI-assisted diagnostic software, as well as the information system for issuing reports. The founder of the company, Zhao Weiguo, has been deeply engaged in the IVD field for more than 30 years, with deep international leadership and management experience in the IVD industry, and is a serial entrepreneur who specializes in creating IVD products with international technological competitiveness. The company's core team comes from well-known enterprises in the medical device industry, with successful industrialization experience in large-scale automated in vitro diagnostic instruments, consumables and reagents.

CYTOWIZ's CYTOWIZ® automatic liquid-based cell preparation, staining and sealing machine, automatic intelligent high-definition microscope scanning technology and artificial intelligence cytology analysis technology, which are independently researched, developed and produced by CYTOWIZ, automate and intelligently integrate the whole process of cervical cytology screening, and possess cutting-edge technological concepts and product innovations both at home and abroad. It solves the problems of non-standardized and low-throughput sample preparation, non-standardized diagnosis and long manual time-consumption, which can promote the release of a large number of potential clinical testing needs, and will bring the domestic pathology department a technical experience similar to that of the modern, fully-automated and intelligent pipeline testing of the laboratory department of large hospitals, which will greatly enhance the efficiency of cytopathology testing in the Department of Pathology and the scale of income generation.    

CYTOWIZ® one-stop cytology intelligence solution:

Quality preparation and clear scanning are prerequisites for cytology AI diagnosis!

CYTOWIZ product innovation highlights:

-Replacing the current semi-automated preparation with fully automated preparation, so that the preparation quality can be significantly improved and repeatability can be guaranteed, thus enhancing the accuracy of AI-assisted diagnosis.

-Reduce the workload of pathologists with efficient AI-assisted diagnosis and alleviate the predicament of severe shortage of pathology cytologists.

CYTOWIZ Innovations:

-All related products of the instrument and its reagents have been licensed, accumulating 13 items. We have applied for more than 30 patents and 2 PCT.

-Products have been sold to many large tertiary hospitals.

-Cell analysis technology platform has matured and can be expanded to fine needle aspiration pathology, urine cells, peripheral blood cells, bladder exfoliated cells and other fields.

Zhao Weiguo, founder of CYTOWIZ, said

Currently, the coverage rate of cervical cancer screening for 400 million women of age between 21 and 65 years old in China is only 25%, and the country requires the screening scope to be expanded to 50% of women of age. Large hospitals still use imported semi-automatic film, naked eye microscopy, coupled with the lack of domestic cytopathologists, according to the current state of the industry, it will take 10 years to complete a national primary screening. Based on such industry background and market demand analysis, we replace the current semi-automated preparation with fully automated preparation through technological innovation, so that the preparation quality can be significantly improved and repeatability can be guaranteed, thus enhancing the accuracy of AI-assisted diagnosis. Then we will use efficient AI-assisted diagnosis to reduce the workload of pathologists, alleviate the predicament of serious shortage of pathology cytologists, effectively improve the diagnostic accuracy of cervical cancer, and make our contribution to accelerate the elimination of cervical cancer.

Mr. He Xin, Founding Partner of Silicon Harbor Capital, said

CYTOWIZ's product development and market research are deeply synergistic, and the products can effectively solve the industry's difficulties and pain points. We see the uniqueness of CYTOWIZ's products and the strengths of the team, and look forward to helping CYTOWIZ further expand the application areas of its products in the future and bring more value to the industry.

Mr. Gu Jiefeng, Deputy General Manager of Zhangke Herun, said

At present, many IVD segments in the high-end market are still firmly controlled by foreign investors, CYTOWIZ is targeting the field of cellular analysis, which is mainly positioned as a domestic alternative to high-end imported products, and the performance of the company's products has a greater advantage than that of similar domestic and foreign manufacturers. We believe that with the right direction and the joint efforts of our team, the development and growth of CYTOWIZ is just around the corner.

About Silicon Harbor Capital

Silicon Harbor Capital is an international investment firm focusing on global early-stage and growth-stage emerging technologies and AI technology applications. Silicon Harbor Capital was founded in 2019 by veteran investor He Xin, and is headquartered in Shanghai. Mr. He Xin was formerly an Associate Director of Intel Capital, President of Carlyle Group China, and President of Rexam Management Group Asia. The other partners of Silicon Harbor Capital are R&D developers of global communication giants and successful serial entrepreneurs in the technology industry, as well as senior executives with R&D and global strategic investment experience in global industrial software giants and renowned semiconductor companies. The investment team brings together top talents with deep insights into the development of semiconductor, industrial software, cloud computing, smart manufacturing-related hardware and software industries, as well as the new generation of smart medical devices.
Silicon Harbor Capital has a long-term focus on the global market, focusing on science and technology, continuously exploring potential high-quality companies through in-depth industry research, accumulating and integrating industrial resources through open communication and seminars, supporting entrepreneurs to continuously innovate, empowering companies to grow at a high speed, and committing to creating excellent investment returns for investors.

About ZKHF

Zhangke Harvest Fund is managed by Zhangjiang Science and Technology Investment, a wholly-owned subsidiary of Zhangjiang Group, with Pudong Science and Technology Innovation Parent Fund as the cornerstone investor. The fund focuses on innovative drugs, medical devices, medical services and other fields. As the biomedical investment platform of Zhangjiang Group, ZKHF relies on the industrial ecology and park resources of Zhangjiang to help high-quality companies with growth potential in life and health related industries to thrive and grow.